$SIBN

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

SI-Bone Inc (SIBN) shares rose 2.8% after receiving FDA 510(k) clearance for its iFuse Granite Onyx System, its first product for spinal fusion outside the pelvis. The system aims to address screw loosening in spinal fusions. CEO Laura Francis noted it is the company's third breakthrough device designation.

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 11, 2026, SI-BONE, Inc. (the “Company”) and BIXBY SPE FINANCE 11, LLC (“Landlord”) entered into the Fourth Amendment to Lease (the “Fourth Lease Amendment”) to the Office Lease Agreement dated as of February 2, 2

FRANCIS LAURA (Chief Executive Officer) sold 25,972 indirectly-held shares of SI-BONE, Inc. (SIBN) at $20.12 ($0.52M total) on 2026-08-24 under a Rule 10b5-1 trading plan.

SI-BONE (SIBN) reported that a trust plans to sell 25,972 shares of its common stock under Rule 144. The shares were acquired from restricted stock units that vested starting May 15, 2021. The filing also details recent sales by the trust and Laura Francis, including 10b5-1 plan transactions.

FRANCIS LAURA (Chief Executive Officer) sold 55,807 indirectly-held shares of SI-BONE, Inc. (SIBN) at an average of $19.50 ($19.46–$20.02, $1.09M total) across 2 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.

FRANCIS LAURA (Chief Executive Officer) sold 14,956 shares of SI-BONE, Inc. (SIBN) at an average of $18.66 ($18.63–$18.68, $0.28M total) across 5 trades on 2026-08-17.

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t

Si-Bone, Inc. (SIBN) is scheduled to report Q2 2026 earnings on Aug. 3 after market close, with results expected at 4:09 PM ET. The consensus outlook cited for the quarter includes revenue of $55.34 million and EPS of -$0.15 (USD).

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. sibn-20260604 0001459839 false 0001459839 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 8-K __________________________________________________________